Victoria’s theatre industry came together on Monday May 5th at the Comedy Theatre to reveal the winners for the 2025 Green ...

Last week, biotech bigwig Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny.

On a positive note, the potential launch of anito-cel in multiple myeloma and Trodelvy in first-line metastatic triple negative breast cancer in 2026 will strengthen the company’s oncology business.

Legend Biotech faces a 60% stock drop amid safety, supply issues, and competition for its CAR-T therapy, Carvykti. See here ...

John McCallion; Executive Vice President and Chief Financial Officer and Head of MetLife Investment Management; MetLife Inc Ramy Tadros; Regional President, U.S. Business, and Head of MetLife Holdings ...

Thank you for joining us for Aflac Incorporated's First Quarter 2025 Earnings Call. This morning, Dan Amos, Chairman and CEO of Aflac Incorporated, will provide an overview of our results and ...

MetLife Inc., a prominent player in the insurance industry with a market capitalization of $52.3 billion, reported its first-quarter 2025 financial results, showcasing strong revenue performance ...